PROSTATE-SPECIFIC ANTIGEN AS A PREDICTOR OF RADIOTHERAPY RESPONSE AND PATTERNS OF FAILURE IN LOCALIZED PROSTATE-CANCER

被引:155
作者
RITTER, MA
MESSING, EM
SHANAHAN, TG
POTTS, S
CHAPPELL, RJ
KINSELLA, TJ
机构
[1] UNIV WISCONSIN, SCH MED, DEPT SURG, MADISON, WI 53792 USA
[2] UNIV WISCONSIN, SCH MED, DEPT STAT, MADISON, WI 53792 USA
关键词
D O I
10.1200/JCO.1992.10.8.1208
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: A study of preradiation and postradiation, serial serum prostate- specific antigen (PSA) levels was performed in patients who had clinically localized prostate cancer. The prognostic value of the PSA in pretreatment evaluation and posttreatment follow-up was assessed. Patients and Methods: Sixty-three patients who presented with clinically localized prostate cancer and who were treated with external-beam radiation therapy were followed-up for a median of 25 months. A serum PSA and physical examination were performed at 3-month intervals, and a bone scan was done yearly. An increase in PSA triggered an additional metastatic workup. Prostate rebiopsy was performed for new, palpable nodules or for a serial increase in PSA in the context of a negative metastatic workup. Results: Forty-one patients remained recurrence-free and 22 recurred clinically, 15 distantly and seven locally. The PSA was the strongest, independent, pretreatment prognostic indicator (P = .019) among pretreatment PSA, stage, and grade, but lost significance when the serum prostatic acid phosphatase (PAP) status was included. The initial rate of the PSA decrease after radiation (median half-life, 2.6 months) failed to predict outcome. Recurrence-free patients reached postradiation PSA levels that were equivalent to those reported in disease-free male populations; failure of the PSA to reach such normal levels was a multivariate predictor of subsequent failure (P < .037). All clinicopathologic documentations of failure were preceded by an increase in PSA levels during follow-up. Delayed versus early PSA increase was associated with clinically localized versus metastatic first recurrence. Conclusions: The serum PSA is an independent pretreatment and posttreatment predictor of outcome. Additionally, for a median follow-up of 25 months, delayed PSA failure is associated with clinically localized rather than metastatic recurrence, a relationship that may help in selection for local salvage therapy.
引用
收藏
页码:1208 / 1217
页数:10
相关论文
共 52 条
  • [1] AHLERING TE, 1988, DIAGNOSIS MANAGEMENT, P454
  • [2] BATES D, 1991, NONLINEAR REGRESSION
  • [3] CARTER HB, 1989, CLIN ASPECTS PROSTAT, P247
  • [4] MEASUREMENT OF PROSTATE-SPECIFIC ANTIGEN IN SERUM AS A SCREENING-TEST FOR PROSTATE-CANCER
    CATALONA, WJ
    SMITH, DS
    RATLIFF, TL
    DODDS, KM
    COPLEN, DE
    YUAN, JJJ
    PETROS, JA
    ANDRIOLE, GL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (17) : 1156 - 1161
  • [5] CHAN DW, 1987, CLIN CHEM, V33, P1916
  • [6] PROGRESS AND PROBLEMS IN SCREENING FOR CARCINOMA OF THE PROSTATE
    CHODAK, GW
    SCHOENBERG, HW
    [J]. WORLD JOURNAL OF SURGERY, 1989, 13 (01) : 60 - 64
  • [7] Conover W.J., 1980, PRACTICAL NONPARAMET
  • [8] Cox DR, 2018, ANAL BINARY DATA
  • [9] TUMOR-MARKERS IN PROSTATIC-CARCINOMA - A COMPARISON OF PROSTATE-SPECIFIC ANTIGEN WITH ACID-PHOSPHATASE
    FERRO, MA
    BARNES, I
    ROBERTS, JBM
    SMITH, PJB
    [J]. BRITISH JOURNAL OF UROLOGY, 1987, 60 (01): : 69 - 73
  • [10] IMMUNOCYTOCHEMICAL LOCALIZATION OF PROSTATE-SPECIFIC ANTIGEN - SPECIFICITY AND APPLICATION TO CLINICAL-PRACTICE
    FORD, TF
    BUTCHER, DN
    MASTERS, JRW
    PARKINSON, MC
    [J]. BRITISH JOURNAL OF UROLOGY, 1985, 57 (01): : 50 - 55